SCHEDULE: Logos Global Reduces Stake in Design Therapeutics

Logos Global Management LP and affiliated entities, including Arsani William, have reduced their beneficial ownership in Design Therapeutics, Inc. to 4.4% following Dr. William's resignation from the board.

Summary

• Logos Global Management LP and its affiliates, including Arsani William, collectively beneficially own 2,515,000 shares of Design Therapeutics, Inc. Common Stock.
• This represents 4.4% of the outstanding Common Stock, based on 56,963,757 shares as of October 31, 2025.
• The filing is an Amendment No. 3 to Schedule 13D, updating previous disclosures.
• Dr. William resigned from the Issuer's board of directors on September 9, 2025.
• Logos Global Master Fund, L.P. sold 620,000 shares at $7.25 per share on November 14, 2025.
• Logos Global Master Fund, L.P. sold an additional 120,000 shares at $7.5035 per share on November 18, 2025.
• The initial acquisition of 1,217,627 shares resulted from the automatic conversion of Preferred Stock immediately prior to the Issuer's initial public offering on March 30, 2021.
• Global Fund acquired 1,500,000 shares for a total purchase price of $3,887,563.90.
• Dr. William was granted options to acquire 15,000 shares of the Stock for his services as a director.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in beneficial ownership by a significant institutional investor and the resignation of their representative from the board, which could be interpreted as a negative signal regarding the company's prospects or the investor's confidence.

Positives

• The reporting persons initially acquired a significant stake, indicating prior confidence in the company's prospects.

Negatives

• Logos Global Master Fund, L.P. sold a total of 740,000 shares in November 2025, reducing their overall exposure.
• Dr. William, a control person of the reporting entities, resigned from the board of directors on September 9, 2025.

Future Outlook

The reporting persons will routinely monitor the Issuer regarding a wide variety of factors that affect their investment considerations. They may purchase additional securities, sell existing holdings, or enter into hedging transactions. They may also communicate with other stockholders and recommend actions to the Issuer's management, board, and stockholders, potentially involving mergers, acquisitions, changes in control, or other capital structure adjustments.

Industry Context

This filing primarily concerns a change in beneficial ownership and a director's departure, rather than broader industry trends. The sale of shares by an institutional investor and former director could signal a shift in investment strategy or outlook for Design Therapeutics, which operates in the biotechnology/pharmaceutical sector.

Management Changes

Legal Proceedings

• None of the reporting persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) in the last five years.
• None of the reporting persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction related to federal or state securities laws in the last five years.

Stakeholder Impact

• Shareholders: The reduction in stake by a significant institutional investor and former director could lead to negative sentiment and potentially impact share price.

Next Steps

• Reporting persons will routinely monitor the Issuer.
• Reporting persons may purchase additional securities or sell existing holdings.
• Reporting persons may enter into or unwind hedging or other derivative transactions.
• Reporting persons may communicate with other stockholders and recommend actions to the Issuer's management, board, and stockholders.

Key Dates

Recommendation

The sale of a substantial block of shares by a major institutional investor, coupled with the resignation of their representative from the board, suggests a potential loss of confidence or a strategic exit. This action by a sophisticated investor could signal underlying concerns about the company's future performance or valuation, warranting a 'sell' recommendation for other investors to consider reducing their exposure.

Keywords

Design Therapeutics, Logos Global Management, Schedule 13D, Beneficial Ownership, Stock Sale, Director Resignation, Common Stock, SEC Filing, Investment Management